Sodium valproate drives propionylation-mediated epigenetic reprogramming to enhance mesothelin CAR-T cell therapy in solid tumors.
Chimeric antigen receptor (CAR)-T cell therapy has shown success in hematologic malignancies but remains limited in solid tumors due to poor persistence, migration, and tumor microenvironment-induced exhaustion. In an investigator-initiated trial in relapsed/refractory ovarian cancer, …